Skip to main content
SpringerLink
Log in

Improvement in OMERACT domains and renal function with regular treatment for gout: a 12-month follow-up cohort study

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

OMERACT proposed a set of mandatory and discretionary domains to evaluate the effect of treatment in patients with gout. To determine the percentage of improvement and the effect size 6 and 12 months after starting a proper treatment in patients with gout from our cohort (GRESGO) based on the OMERACT proposal for chronic gout. GRESGO is a cohort of consecutive, new patients with gout attending either of two dedicated clinics. This report includes 141 patients evaluated at baseline and 6 months plus 101 of them completing a 12-month follow-up in 2012. Clinical data including the OMERACT domains for chronic gout were collected at baseline and every 6 months. Treatment was prescribed by their attending physician with the purpose of getting < 6 mg/dL of seric uric acid (sUA). Most patients were males (96%) with inappropriate treatment (95%); 66% had tophi, 30% metabolic syndrome, and 32% low renal function. Mean dose of allopurinol at baseline and throughout the study went from 344 ± 168 mg/day to 453 ± 198 at 12 months. Most OMERACT domains and renal function improved significantly; 73% improved > 20% from 6 to 12 months. Greater improvement was observed in the domains: flares, index tophus size, pain, general health assessment, and HAQ score, all of them associated to lower sUA values. Chronic gout patients improve significantly in most OMERACT domains when conventional and regular treatment is indicated. sUA < 6 mg/dL is associated with greater improvement.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M (2015) Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis 74:661–667

    Article  PubMed  Google Scholar 

  2. Wise E, Khanna PP (2015) The impact of gout guidelines. Curr Op Rheumatol 27:225–230

    Article  Google Scholar 

  3. Dalbeth N, McQueen FM, Singh JA et al (2011) Tophus measurement as an outcome measure for clinical trials of chronic gout: progress and research priorities. J Rheumatol 38:1458–1461

    Article  PubMed  Google Scholar 

  4. Schumacher HR Jr, Edwards LN, Perez-Ruiz F et al (2005) OMERACT 7 special interest group. Outcome measures for acute and chronic gout. J Rheumatol 32:2452–2455

    PubMed  Google Scholar 

  5. Taylor WJ, Schumacher HR Jr, Baraf HS et al (2008) A modified Delphi exercise to determine the extent of consensus with OMERACT outcome domains for studies of acute and chronic gout. Ann Rheum Dis 67:888–891

    Article  PubMed  CAS  Google Scholar 

  6. Schumacher HR, Taylor W, Joseph-Ridge N, Perez-Ruiz F, Chen LX, Schlesinger N, Khanna D, Furst DE, Becker MA, Dalbeth N, Edwards NL (2007) Outcome evaluations in gout. J Rheumatol 34:1381–1385

    PubMed  Google Scholar 

  7. Schumacher HR, Taylor W, Edwards L et al (2009) Outcome domains for studies of acute and chronic gout. J Rheumatol 36:342–345

    Article  Google Scholar 

  8. Singh JA, Taylor WJ, Simon LS et al (2011) Patient-reported outcomes in chronic gout: a report from OMERACT 10. J Rheumatol 38:1452–1457

    Article  PubMed  Google Scholar 

  9. Taylor WJ, Singh JA, Saag KG et al (2011) Bringing it all together: a novel approach to the development of response criteria for chronic gout clinical trials. J Rheumatol 38:1467–1470

    Article  PubMed  Google Scholar 

  10. Taylor WJ, Brown M, Aati O, Weatherall M, Dalbeth N (2013) Do patient preferences for core outcome domains for chronic gout studies support the validity of composite response criteria? Arthritis Care Res 65:1259–1264

    Article  Google Scholar 

  11. Diaz-Torne C, Pou MA, Castellvi I, Corominas H, Taylor WJ (2014) Concerns of patients with gout are incompletely captured by OMERACT-endorsed domains of measurement for chronic gout studies. J Clin Rheumatol 20:138–140

    Article  PubMed  Google Scholar 

  12. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yü TF (1977) Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 20:895–900

    Article  PubMed  CAS  Google Scholar 

  13. Vázquez-Mellado J, Hernández-Cuevas CB, Alvarez-Hernández E, Ventura-Rios L, Peláez-Ballestas I, Casasola-Vargas J, García-Méndez S, Burgos-Vargas R (2012) The diagnostic value of the proposal for clinical gout diagnosis (CGD). Clin Rheumatol 31:429–434

    Article  PubMed  Google Scholar 

  14. Neogi T, Jansen TL, Dalbeth N et al (2015) 2015 gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheumatol 67:2557–2568

    Article  PubMed  PubMed Central  Google Scholar 

  15. Herdman M, Badía X, Berra S (2001) EuroQol-5D: a simple alternative for measuring health-related quality of life in primary care. Aten Primaria 28:425–430

    Article  PubMed  CAS  Google Scholar 

  16. Alvarez-Hernández E, Peláez-Ballestas I, Vázquez-Mellado J et al (2008) Validation of the health assessment questionnaire disability index in patients with gout. Arthritis Rheum 15:665–669

    Article  Google Scholar 

  17. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 285:2486–2497

    Article  Google Scholar 

  18. Marathe PH, Gao HX, Close KL (2017) American Diabetes Association standards of medical Care in Diabetes 2017. J Diabetes 9:320–324

    Article  PubMed  Google Scholar 

  19. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 130:461–470

    Article  PubMed  CAS  Google Scholar 

  20. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2012) KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3:1–150

    Google Scholar 

  21. Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, Kaldas M, Gogia M, Perez-Ruiz F, Taylor W, Lioté F, Choi H, Singh JA, Dalbeth N, Kaplan S, Niyyar V, Jones D, Yarows SA, Roessler B, Kerr G, King C, Levy G, Furst DE, Edwards NL, Mandell B, Schumacher HR, Robbins M, Wenger N, Terkeltaub R, American College of Rheumatology (2012) 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res 64:1431–1446

    Article  CAS  Google Scholar 

  22. Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, Coyfish M, Guillo S, Jansen TL, Janssens H, Lioté F, Mallen C, Nuki G, Perez-Ruiz F, Pimentao J, Punzi L, Pywell T, So A, Tausche AK, Uhlig T, Zavada J, Zhang W, Tubach F, Bardin T (2017) 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 76:29–42

    Article  PubMed  CAS  Google Scholar 

  23. Husted JA, Cook RJ, Farewell VT, Gladman D (2000) Methods for assessing responsiveness a critical review and recommendations. J Clin Epidemiol 53:459–468

    Article  PubMed  CAS  Google Scholar 

  24. García-Méndez S, Rivera-Bahena CB, Montiel-Hernández JL et al (2015) A Prospective follow-up of adipocytokines in cohort patients with gout. Association with metabolic syndrome but not with clinical inflammatory findings: strobe-compliant article. Medicine 94:e935

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  25. Pérez Ruiz F, Atxotegi J, Hernado I, Calabozo M, Nolla JM (2006) Using serum urate levels to determine the period free of gout symptoms after withdrawal of long-term urate-lowering therapy: a prospective study. Arthritis Rheum 55:786–790

    Article  PubMed  CAS  Google Scholar 

  26. Perez Ruiz F, Lioté F (2007) Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout? Arthritis Rheum 57:1324–1328

    Article  PubMed  Google Scholar 

  27. Pascual E, Andrés M, Vela P (2013) Gout treatment: should we aim for rapid crystal dissolution? Ann Rheum Dis 72:635–637

    Article  PubMed  CAS  Google Scholar 

  28. Stamp LK, Khanna PJ, Dalbeth N et al (2011) Serum urate in chronic gout—will it be the first validated soluble biomarker in rheumatology? J Rheumatol 38:1462–2466

    Article  PubMed  PubMed Central  Google Scholar 

  29. Corbett EJ, Pentony P, McGill NW (2017) Achieving serum urate targets in gout and audit in a gout-oriented rheumatology practice. Int J Rheum Dis 20:894–897

    Article  PubMed  Google Scholar 

  30. Slot O (2017) Gout in a rheumatology clinic: results of EULAR/ACR guidelines compliant treatment. Scand J Rheumatol 11:1–4

    Google Scholar 

  31. Saag K, Fitz-Patrick D, Kopicko J et al (2017) Lesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-based study). Arthritis Rheumatol 69:203–212

    Article  PubMed  CAS  Google Scholar 

  32. Hughes JC, Wallace JL, Bryant CL, Salvig BE, Fourakre TN, Stone WJ (2017) Monitoring of Urate-lowering therapy among US veterans following the 2012 American College of Rheumatology Guidelines for Management of Gout. Ann Pharmacother 51:301–306

    Article  PubMed  CAS  Google Scholar 

  33. Peláez-Ballestas I, Boonen A, Vázquez-Mellado J et al (2015) Coping strategies for health and daily-life stressors in patients with rheumatoid arthritis, ankylosing spondylitis, and gout: STROBE-compliant article. REUMAIMPACT Group Med 94:e600

    Google Scholar 

  34. López López CO, Lugo EF, Alvarez-Hernández E, Peláez-Ballestas I, Burgos-Vargas R, Vázquez-Mellado J (2017) Severe tophaceous gout and disability: changes in the past 15 years. Clin Rheumatol 36:199–204

    Article  PubMed  Google Scholar 

  35. Kiltz U, Smolen J, Bardin T, Cohen Solal A, Dalbeth N, Doherty M, Engel B, Flader C, Kay J, Matsuoka M, Perez-Ruiz F, da Rocha Castelar-Pinheiro G, Saag K, So A, Vazquez Mellado J, Weisman M, Westhoff TH, Yamanaka H, Braun J (2017) Treat to target (T2T) recommendations for gout. Ann Rheum Dis 76:632–638

    Article  PubMed  CAS  Google Scholar 

  36. Shekelle PG, Newberry J, Fitzgerald JD et al (2017) Management of gout: a systematic review in support of an American College of Physicians Clinical Practice Guideline. Ann Intern Med 166:37–51

    Article  PubMed  Google Scholar 

  37. Fitzgerald JD, Neogi T, Choi HK (2017) Editorial: do not let gout apathy lead to gouty arthropathy. Arthritis Rheumatol 69:479–482

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Aarón Vazquez Mellado MO and Ma. Eugenia Sanchez Girard as research assistants for the GRESGO cohort.

Funding

This project received unrestricted partial financial support from Unidad de Investigación, Colegio Mexicano de Reumatología; Servicio de Reumatología and Dirección de Investigación, Hospital General de México and Takeda, México.

Author information

Authors and Affiliations

  1. Rheumatology Department, Hospital General de México Eduardo Liceaga México City, México City, Mexico

    Janitzia Vazquez-Mellado, Ingris Peláez-Ballestas, Rubén Burgos-Vargas, Everardo Alvarez-Hernández & Sergio García-Méndez

  2. Facultad de Medicina, Universidad Nacional Autónoma de México, México City, Mexico

    Janitzia Vazquez-Mellado, Ingris Peláez-Ballestas, Rubén Burgos-Vargas, Everardo Alvarez-Hernández, Virginia Pascual-Ramos & Marina Rull-Gabayet

  3. Immunology and Rheumatology Department, Instituto Nacional de Ciencias Médicas y de la Nutrición Salvador Zubirán, Mexico City, Mexico

    Virginia Pascual-Ramos & Marina Rull-Gabayet

Authors
  1. Janitzia Vazquez-Mellado
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ingris Peláez-Ballestas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rubén Burgos-Vargas
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Everardo Alvarez-Hernández
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sergio García-Méndez
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Virginia Pascual-Ramos
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Marina Rull-Gabayet
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Janitzia Vazquez-Mellado.

Ethics declarations

The ethics and research committees of both centers approved the study protocol. The study was conducted in accordance with the principles contained in the Declaration of Helsinki. All patients were informed about the procedures of the study and provided written informed consent.

Disclosures

None.

Electronic supplementary material

ESM 1

(XLSX 14 kb).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vazquez-Mellado, J., Peláez-Ballestas, I., Burgos-Vargas, R. et al. Improvement in OMERACT domains and renal function with regular treatment for gout: a 12-month follow-up cohort study. Clin Rheumatol 37, 1885–1894 (2018). https://doi.org/10.1007/s10067-018-4065-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-018-4065-7

Keywords

Search

Navigation